Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company that focuses on developing and selling foam-based products for the treatment of various skin conditions, including acne and impetigo. Their lead product candidates, FMX101 and FMX102, have completed Phase II clinical trials and show promise in treating moderate-to-severe acne and methicillin-resistant staphylococcus aureus-caused impetigo, respectively. The company operates in the United States, Germany, and Israel.